In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models.

Abstract

Given the very limited efficacy of doxorubicin (doxo) in soft tissue sarcoma, there is a clear need for more active and less toxic treatments for this family of diseases. However, due to the rarity of these malignancies and lack of reliable preclinical models, development of new therapies has lagged behind. We evaluated the efficacy of PhAc-ALGP-doxorubicin… (More)
DOI: 10.1158/1535-7163.MCT-16-0832

Topics

Cite this paper

@article{Cornillie2017InVA, title={In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models.}, author={Jasmien Cornillie and Agnieszka Wozniak and Peter Pokreisz and Andrea Casazza and Lise Vreys and Jasmien Wellens and Ulla Vanleeuw and Yemarshet Kelemework Gebreyohannes and Maria Debiec-Rychter and Raf Sciot and Daphne Hompes and Patrick Sch{\"o}ffski}, journal={Molecular cancer therapeutics}, year={2017}, volume={16 8}, pages={1566-1575} }